Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Current Liabilities (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Total Current Liabilities for 10 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 28.31% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 28.31% year-over-year, with the annual reading at $1.2 billion for FY2025, 28.31% up from the prior year.
  • Total Current Liabilities hit $1.2 billion in Q4 2025 for Ascendis Pharma A, up from $970.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $1.2 billion in Q4 2025 to a low of $114.8 million in Q4 2021.
  • Historically, Total Current Liabilities has averaged $659.4 million across 5 years, with a median of $792.4 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: soared 353.5% in 2023 and later grew 22.42% in 2024.
  • Year by year, Total Current Liabilities stood at $114.8 million in 2021, then surged by 52.21% to $174.7 million in 2022, then soared by 353.5% to $792.4 million in 2023, then grew by 22.42% to $970.1 million in 2024, then increased by 28.31% to $1.2 billion in 2025.
  • Business Quant data shows Total Current Liabilities for ASND at $1.2 billion in Q4 2025, $970.1 million in Q4 2024, and $792.4 million in Q4 2023.